Add BrightSurf on Google Email

New study finds cystic fibrosis drug allows patients to safely scale back lung therapies

A multi-site study led by CU Anschutz researchers found that people with cystic fibrosis who start triple-drug therapy elexacaftor/tezacaftor/ivacaftor (ETI) can safely reduce many daily lung treatments while maintaining good health for years. The study showed a steady decline in the use of chronic respiratory therapies, including hype...

SourceUniversity of Colorado Anschutz·JournalJournal of Cystic Fibrosis·DateDec 4, 2025

All life copies DNA unambiguously into proteins. Archaea may be the exception.

Researchers discovered that one microorganism can live with a bit of ambiguity in its genetic code, synthesizing two different proteins seemingly at random. This finding contradicts a long-held dogma and has implications for future disease therapies, including treating diseases caused by premature stop codons.

SourceUniversity of California - Berkeley·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateDec 1, 2025

Medical School research laboratory team awarded $11.3M to study innovative tools to treat genetic disorders

A research team led by the University of Minnesota Medical School will investigate alternative genetic decoding in single-celled organisms and identify readthrough-inducing drugs to treat genetic disorders caused by premature termination codons. The goal is to restore normal function of genes and proteins in cells, potentially helping ...

Missing molecule may explain Down syndrome

Scientists found a promising candidate, pleiotrophin, which is essential for brain development and function; restoring it may improve brain circuits in individuals with Down syndrome and other neurological diseases. The study's findings suggest using modified viruses to deliver the protein directly into cells could lead to new treatments.

SourceUniversity of Virginia Health System·JournalCell Reports·DateOct 17, 2025

New EndoCompass Research Roadmap calls for coordinated investment to tackle Europe’s hormone health challenge

The European Society of Endocrinology has released the EndoCompass Research Roadmap, a major new initiative to align research efforts and improve funding strategies for hormone-related health challenges. The roadmap identifies specific research needs across eight endocrine specialties and five cross-cutting areas.

SourceEuropean Society of Endocrinology·TypeCommentary/editorial·DateOct 17, 2025

Catching Alport syndrome through universal age-3 urine screening

Researchers found that over 30% of children referred for Alport syndrome testing at age 3 already required therapeutic intervention, highlighting the potential benefits of early detection. The study suggests introducing a urine testing system may enable intervention before kidney dysfunction onset.

SourceKobe University·JournalKidney International Reports·TypeData/statistical analysis·DateOct 7, 2025

Stowers scientists identify the fusion point of Robertsonian chromosomes, hinting at how chromosomes evolve

Researchers at Stowers Institute for Medical Research have identified the precise location where human chromosomes break and recombine to form Robertsonian chromosomes. The study reveals that repetitive DNA sequences play a central role in genome organization and evolution, explaining how these rearrangements form and remain stable.

SourceStowers Institute for Medical Research·JournalNature·TypeExperimental study·DateSep 24, 2025

Family Heart Foundation announces recommendations to improve universal screening for underdiagnosed genetic condition in children, which causes early onset cardiovascular disease

A multidisciplinary panel published in the Journal of Pediatrics advocates for accelerated diagnosis of familial hypercholesterolemia, a life-threatening genetic condition. Universal lipid screening is recommended to identify affected children at high risk of heart disease decades earlier than those without the condition.

SourceFamily Heart Foundation·JournalThe Journal of Pediatrics·TypeSystematic review·DateSep 23, 2025

CRISPR’s efficiency triples with DNA-wrapped nanoparticles

Researchers at Northwestern University have developed a new CRISPR delivery system that triples efficiency using DNA-wrapped nanoparticles, improving safety and effectiveness. The new system, called LNP-SNAs, targets specific cells and tissues, reducing toxicity and boosting gene-editing efficiency by threefold.

SourceNorthwestern University·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateSep 1, 2025

Retinitis pigmentosa mouse models reflect pathobiology of human RP59

Scientists at the University of Alabama at Birmingham created novel mouse models with mutations in the DHDDS gene to study retinitis pigmentosa (RP) 59, a genetic cause of blindness. The studies revealed that both T206A/K42E and K42E/K42E mouse models exhibited changes in retinal structure and function similar to human RP59 disease.

SourceUniversity of Alabama at Birmingham·JournalDisease Models & Mechanisms·TypeExperimental study·DateAug 29, 2025

A stunning first look at the viruses inside us

Researchers mapped the surface envelope glycoprotein of human endogenous retroviruses, opening doors to new diagnostic and therapeutic opportunities. The study revealed specific antibodies that target the viral proteins, potentially leading to new cancer immunotherapies and treatments for autoimmune diseases.

SourceLa Jolla Institute for Immunology·JournalScience Advances·TypeExperimental study·DateAug 27, 2025

Breakthrough discovery reveals how connection between mitochondrial vulnerability and neurovasculature function impacts neuropsychiatric disease

Researchers from the University of Pennsylvania School of Veterinary Medicine and Children's Hospital of Philadelphia discovered a link between mitochondrial dysfunction in the blood-brain barrier and neuropsychiatric disease in patients with 22qDS. Treatment with bezafibrate, a cholesterol drug, may enhance BBB function and correct so...

SourceChildren's Hospital of Philadelphia·JournalScience Translational Medicine·TypeExperimental study·DateAug 20, 2025

Promising new method could treat inherited diseases

Researchers at the University of Waterloo have developed a novel method using modified M13 bacteria to deliver targeted gene therapies for genetic disorders. This approach shows promise as a cost-effective alternative to current methods, which can be expensive and trigger toxic side effects.

SourceUniversity of Waterloo·JournalMolecular Therapy — Nucleic Acids·TypeExperimental study·DateAug 20, 2025

Phase I/II clinical study of gene therapy for GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases, shows encouraging results

A Phase I/II clinical trial found that gene therapy reduced seizures, improved oral feeding, and increased production of the HexA enzyme. Participants experienced fewer and more controllable seizures, and some remained on full oral feeds for up to 27 months.

SourceUMass Chan Medical School·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateAug 18, 2025

Children’s Hospital of Philadelphia, Clinic for Special Children discover ultra rare form of neuroinflammatory disease is much more common in Old Order Amish than general population

Researchers from CHOP and Clinic for Special Children discovered a genetic disorder affecting the immune system is prevalent in the Old Order Amish community. The study found that complement factor I deficiency, an ultra-rare genetic disorder causing debilitating neuroinflammation, is more common in individuals of Old Order Amish ances...

SourceChildren's Hospital of Philadelphia·JournalJournal of Allergy and Clinical Immunology·TypeCase study·DateAug 12, 2025

AI meets CRISPR for precise gene editing

A research team developed a new method to precisely edit DNA by combining genetic engineering with artificial intelligence. The technique enables accurate modeling of human diseases and lays the groundwork for next-generation gene therapies.

SourceUniversity of Zurich·JournalNature Biotechnology·TypeExperimental study·DateAug 12, 2025

New label-free 3D imaging technology offers breakthrough in diagnosing and treating lysosomal storage diseases

Researchers have developed a groundbreaking method to observe lysosomes in live suspended cells—quantitatively, in 3D, and without the use of chemical labels. The technology uses holographic tomography in flow cytometry configuration (HTFC) to identify morphological and spatial lysosomal changes in models of lysosomal storage diseases.

SourceFondazione Telethon·JournalACS Nano·TypeExperimental study·DateAug 6, 2025